Compare Stocks: KMDA, LKFT, ZYME, and VIR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KMDA Kamada	$8.77 -1.1%	$7.80	$6.50 ▼ $9.35	$510.07M	0.88	150,555 shs	138,596 shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$30.72 +1.8%	$28.24	$25.68 ▼ $37.78	$1.99B	0.28	271,003 shs	635,291 shs
VIR Vir Biotechnology	$11.09 -3.6%	$9.96	$4.82 ▼ $11.94	$1.95B	1.63	2.21 million shs	1.68 million shs
ZYME Zymeworks	$27.50 -0.3%	$25.90	$15.81 ▼ $31.34	$1.96B	1.19	675,950 shs	647,744 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KMDA Kamada	-1.13%	+7.08%	+4.03%	+22.14%	+26.73%
LKFT Lakefront Biotherapeutics American Depositary Shares	+1.76%	+11.59%	+5.79%	+6.52%	-8.41%
VIR Vir Biotechnology	-3.57%	+5.42%	+11.91%	+12.25%	+114.51%
ZYME Zymeworks	-0.25%	+4.80%	-4.41%	+15.69%	+68.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KMDA Kamada	$8.77 -1.1%	$7.80	$6.50 ▼ $9.35	$510.07M	0.88	150,555 shs	138,596 shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$30.72 +1.8%	$28.24	$25.68 ▼ $37.78	$1.99B	0.28	271,003 shs	635,291 shs
VIR Vir Biotechnology	$11.09 -3.6%	$9.96	$4.82 ▼ $11.94	$1.95B	1.63	2.21 million shs	1.68 million shs
ZYME Zymeworks	$27.50 -0.3%	$25.90	$15.81 ▼ $31.34	$1.96B	1.19	675,950 shs	647,744 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KMDA Kamada	-1.13%	+7.08%	+4.03%	+22.14%	+26.73%
LKFT Lakefront Biotherapeutics American Depositary Shares	+1.76%	+11.59%	+5.79%	+6.52%	-8.41%
VIR Vir Biotechnology	-3.57%	+5.42%	+11.91%	+12.25%	+114.51%
ZYME Zymeworks	-0.25%	+4.80%	-4.41%	+15.69%	+68.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KMDA Kamada	3.00	Buy	$13.50	53.93% Upside
LKFT Lakefront Biotherapeutics American Depositary Shares	2.56	Moderate Buy	$37.00	20.44% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$21.57	94.51% Upside
ZYME Zymeworks	2.75	Moderate Buy	$41.00	49.09% Upside

Current Analyst Ratings Breakdown

Latest KMDA, LKFT, ZYME, and VIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy
9/23/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sector Perform ➝ Outperform	$26.00 ➝ $45.00
9/22/2026	KMDA Kamada	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B-)
9/18/2026	KMDA Kamada	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
9/17/2026	ZYME Zymeworks	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/16/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/3/2026	ZYME Zymeworks	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$31.00 ➝ $33.00
8/27/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/26/2026	ZYME Zymeworks	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$32.00
8/26/2026	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/26/2026	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KMDA Kamada	$180.46M	2.79	$0.60 per share	14.52	$4.68 per share	1.87
LKFT Lakefront Biotherapeutics American Depositary Shares	$990.57M	2.04	$0.74 per share	41.58	$47.57 per share	0.65
VIR Vir Biotechnology	$302.59M	6.20	N/A	N/A	$5.50 per share	2.02
ZYME Zymeworks	$105.96M	18.42	N/A	N/A	$3.59 per share	7.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KMDA Kamada	$20.20M	$0.38	23.08	14.62	0.72	11.60%	8.37%	5.85%	11/9/2026 (Estimated)
LKFT Lakefront Biotherapeutics American Depositary Shares	$363.05M	-$1.41	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	-$437.99M	-$1.86	N/A	N/A	N/A	-638.88%	-29.99%	-23.62%	11/4/2026 (Estimated)
ZYME Zymeworks	-$81.13M	-$2.02	N/A	53.92	N/A	-405.31%	-72.30%	-37.18%	11/5/2026 (Estimated)

Latest KMDA, LKFT, ZYME, and VIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KMDA Kamada	$0.1125	$0.16	+$0.0475	$0.16	$50.84 million	$54.92 million
8/10/2026	Q2 2026	LKFT Lakefront Biotherapeutics American Depositary Shares	-$0.9672	$0.04	+$1.0072	$0.04	$7.29 million	$15.47 million
8/7/2026	Q2 2026	ZYME Zymeworks	-$0.5620	-$0.62	-$0.0580	-$0.62	$4.54 million	$3.23 million
8/5/2026	Q2 2026	VIR Vir Biotechnology	$0.3326	$0.47	+$0.1374	$0.47	$135.88 million	$238.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KMDA Kamada	$0.13	1.48%	N/A	34.21%	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Latest KMDA, LKFT, ZYME, and VIR Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/17/2026	KMDA Kamada	annual	$0.17	2.06%	8/27/2026	8/27/2026	9/17/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KMDA Kamada	N/A	4.06	2.29
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	32.84	32.72
VIR Vir Biotechnology	N/A	6.04	6.04
ZYME Zymeworks	N/A	6.32	6.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KMDA Kamada	20.38%
LKFT Lakefront Biotherapeutics American Depositary Shares	32.46%
VIR Vir Biotechnology	65.32%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
KMDA Kamada	36.10%
LKFT Lakefront Biotherapeutics American Depositary Shares	2.91%
VIR Vir Biotechnology	2.90%
ZYME Zymeworks	33.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KMDA Kamada	462	57.51 million	36.75 million	Optionable
LKFT Lakefront Biotherapeutics American Depositary Shares	1,310	65.90 million	63.98 million	Optionable
VIR Vir Biotechnology	367	169.22 million	164.31 million	Optionable
ZYME Zymeworks	264	70.96 million	47.18 million	N/A

KMDA, LKFT, ZYME, and VIR Headlines

Recent News About These Companies

Zymeworks Completes Acquisition of Theravance Biopharma

September 23 at 4:01 PM | globenewswire.com

Head-To-Head Survey: Zymeworks (NASDAQ:ZYME) & Alnylam Pharmaceuticals (NASDAQ:ALNY)

September 23 at 4:16 AM | americanbankingnews.com

Squarepoint Ops LLC Reduces Holdings in Zymeworks Inc. $ZYME

September 22 at 3:36 AM | marketbeat.com

Zymeworks stock gains on fresh Wolfe Research coverage

September 21 at 5:17 PM | ad-hoc-news.deA

Zymeworks stock gains on merger approval and a $41 target

September 20, 2026 | ad-hoc-news.deA

Zymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of "Moderate Buy" from Analysts

September 20, 2026 | americanbankingnews.com

Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Moderate Buy" from Brokerages

September 20, 2026 | marketbeat.com

Theravance Shareholders Approve Merger with Zymeworks Inc.

September 18, 2026 | tipranks.com

Wolfe Research Begins Coverage on Zymeworks (NASDAQ:ZYME)

September 17, 2026 | marketbeat.com

Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 238,026 Shares of Zymeworks Inc. $ZYME

September 12, 2026 | marketbeat.com

Wellington Management Group LLP Takes $2.88 Million Position in Zymeworks Inc. $ZYME

September 11, 2026 | marketbeat.com

Legal & General Group Plc Makes New $1.13 Million Investment in Zymeworks Inc. $ZYME

September 8, 2026 | marketbeat.com

Bank of New York Mellon Corp Acquires New Holdings in Zymeworks Inc. $ZYME

September 7, 2026 | marketbeat.com

Zymeworks stock gains analyst support after FDA cancer therapy approval

September 4, 2026 | ad-hoc-news.deA

JPMorgan Chase & Co. Boosts Zymeworks (NASDAQ:ZYME) Price Target to $33.00

September 3, 2026 | marketbeat.com

Zymeworks (NASDAQ:ZYME) Hits New 1-Year High - Time to Buy?

September 2, 2026 | marketbeat.com

Man Group plc Invests $5.51 Million in Zymeworks Inc. $ZYME

August 30, 2026 | marketbeat.com

4,251,030 Shares in Zymeworks Inc. $ZYME Bought by BlackRock Inc.

August 30, 2026 | marketbeat.com

Zymeworks stock holds near $28.27 as market cap tops $2.01 billion

August 29, 2026 | ad-hoc-news.deA

Zymeworks (ZYME), What Is Behind The Renewed Attention?

August 28, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA, LKFT, ZYME, and VIR Company Descriptions

Kamada NASDAQ:KMDA

$8.77 -0.10 (-1.13%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$8.69 -0.08 (-0.90%)

As of 06:44 AM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

$30.72 +0.53 (+1.76%)

As of 09/23/2026 04:00 PM Eastern

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Vir Biotechnology NASDAQ:VIR

$11.09 -0.41 (-3.57%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$11.00 -0.09 (-0.80%)

As of 04:00 AM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Zymeworks NASDAQ:ZYME

$27.50 -0.07 (-0.25%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$27.29 -0.21 (-0.76%)

As of 05:44 AM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KMDA, LKFT, ZYME, and VIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KMDA, LKFT, ZYME, and VIR Earnings

Compare Dividends

Latest KMDA, LKFT, ZYME, and VIR Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KMDA, LKFT, ZYME, and VIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA, LKFT, ZYME, and VIR Company Descriptions

Kamada NASDAQ:KMDA

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Vir Biotechnology NASDAQ:VIR

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KMDA, LKFT, ZYME, and VIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KMDA, LKFT, ZYME, and VIR Earnings

Compare Dividends

Latest KMDA, LKFT, ZYME, and VIR Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KMDA, LKFT, ZYME, and VIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA, LKFT, ZYME, and VIR Company Descriptions

Kamada NASDAQ:KMDA

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Vir Biotechnology NASDAQ:VIR

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools